Only recently have data been published attempting to validate a technology and technique suitable for targeted delivery of biological payloads to the human spinal cord. OBJECTIVE: To characterize the development and evolution of a spine-stabilized microinjection platform as a vehicle for biologics delivery to the cervical and thoracolumbar spine on the basis of preclinical experience in both non-Good Laboratory Practice (GLP) experimental series and GLP studies. METHODS: Our laboratory completed . 100 cervical and lumbar porcine microinjection procedures between July 2004 and June 2010. This included both non-GLP-and GLPadherent survival series to validate the safety and accuracy achievable with intraspinal microinjection. During this time, 3 different microinjection platforms, injection stages, and cannula designs were tested. RESULTS: Repetitive technological improvements reduced incision length, decreased procedural complexity, and simplified ventral horn targeting and accuracy. These changes reduced procedural invasiveness and the likelihood of neurological morbidity while improving targeting accuracy. In part as a result of these technological improvements and procedural modifications, we have safely progressed from single unilateral microinjections to multiple bilateral injections without long-term neurological sequelae. CONCLUSION: Technological and procedural refinements have significantly enhanced the capabilities of intraspinal microinjection-based biologics delivery. Reductions in procedural invasiveness and the capability to deliver sequential biological payloads effectively have broadened the flexibility of intraspinal microinjection to a widened array of intrinsic spinal cord pathologies. These advances have laid the groundwork for clinical translation of spinal cord microinjections.
I
n small-animal models, spinal cord injections are routinely performed without guidance or stabilization. In some cases, rodent stereotactic apparatuses have been used. These apparatuses provide x/y/z micromanipulation but do little to immobilize the animal with respect to the mounted stereotactic arm. To the extent that such immobilization has been achieved, the animal is fixed relative to the external stereotactic platform and micromanipulator. This would be prohibitively bulky in human application, creating a barrier to the delicate surgery required for spinal intraparenchymal injections.
Human spinal cord injections have historically been performed with a free-hand syringe or a table-mounted pump device. [1] [2] [3] [4] [5] [6] [7] Free-hand intraspinal injection represents an ill-advised delivery strategy in humans for a variety of reasons: (1) It cannot reliably reproduce anatomic targeting of the specific structures (eg, ventral horn in motor neuron disease, plaques in multiple sclerosis); (2) movement of the unsteady needle can shear white matter tracts; (3) the uncontrolled infusion rate has an increased potential for spinal cord mass effect and elevated intraparenchymal pressure; and (4) it provides an imprecise rate of infusion and may predispose to reflux along the catheter track. Table- mounted devices offer the theoretical benefit of improved stability, control of injection speed and volume, and precise 3-dimensional anatomic targeting when coupled with precision micromanipulators/microinjection pumps. However, this strategy still allows movement of the patient and spinal cord with respect to the injection cannula. Cardiovascular pulsation of the spinal cord, ventilation-associated cord movement, inadvertent patient movement, or accidental movement of the injection apparatus may lead to potential injury. Cardiovascular pulsation defines the beat-to-beat pulsation of the spinal cord resulting from blood flow; ventilation-associated cord movement refers to an elevation of the spine and spinal cord several millimeters relative to the bed with ventilation. Both can cause displacement of the cord with respect to the injection cannula.
To address these concerns of increased morbidity and suboptimal accuracy, we developed both stabilized microinjection platforms capable of bony spinal attachment and injection cannulas that either remain immobilized relative to or move with the spinal cords. 8, 9 Specifically, we have designed cervical and thoracolumbar spinal cord microinjection platforms and rigid and floating cannula systems for safe and accurate spinal cord microinjection. These technologies and techniques have been assessed in both Good Laboratory Practice-based studies and non-Good Laboratory Practice experimental series. Since FIGURE 1. The a (lumbar) microinjection platform attached to T11-L2 on a model of human spine with a T12-L1 laminectomy defect. A and B, side and three-quarters views of the a microinjection platform and injector stage overlying the laminectomy defect. C, side view of the device with the Narishige MO-97 hydraulic microdrive attached. D, three-quarters view of the microinjection platform and microinjector with the rigid cannula attached while overlying the laminectomy defect. their introduction, device and procedural modifications have resulted in reduced incision length, improved device stability, reduced injection trauma to the spinal cord, and improvements in injection accuracy. This article summarizes the stepwise progression of design improvements resulting in the currentgeneration spine-stabilized microinjection platform and cannula, as well as the approach approved for phase I clinical translation by the US Food and Drug Administration.
EVOLUTION OF DESIGN
To date, we have conducted . 18 porcine intraspinal microinjection studies evaluating procedural safety and graft viability when injecting biological payloads (eg, cell suspensions and viral vectors) into both the cervical and lumbar spinal cord. Our initial attempts to deliver biological payloads to the lumbar spinal cord used microelectrode recording (MER)-based targeting, an injection platform stabilized to the porcine spinous processes, and a rigid injection cannula. Subsequent changes in platform and cannula design and related improvements in targeting currently allow cervical and thoracolumbar injections, single and multiple injections, improved accuracy, and reduced invasiveness. Changes in the design of each associated component, including the microinjection platform, micromanipulator, targeting methodology, and injection cannula, are described. Figure 1A through 1D demonstrates the a injection platform, designed for lumbar microinjection and accommodating rostral and caudal spinous process attachment over single-level or multilevel laminectomy lengths. Figure 2A and 2D demonstrates the associated injection stage and micromanipulator initially used with this platform. It rigidly affixes to the rail system connecting the rostral and caudal spinous process clamps. The injection stage accommodates rostrocaudal translation of the injection cannula, whereas the Narishige MO-97 micromanipulator (Narishige Scientific Instrument Laboratory, Tokyo, Japan), shown in Figures 1C, 1D , and 2D, allows final positioning with several millimeters of both rostrocaudal and mediolateral translational adjustment. This platform addressed shared limitations of external fixation, table-mounted platforms, and freehand-based approaches by being stabilized with respect to the patient. Advantages include a reduction of respiratory-associated cord movement and reduced risk of inadvertent patient movement resulting in spinal cord trauma. Figure 3A through 3D demonstrates the b cervical microinjection platform, designed to replicate the stabilization capabilities of the a platform by rostral fixation to the porcine occiput and caudal attachment to the C7 spinous process. 8 Whereas the a platform used only spinous process pressure clamps for fixation, the cervical microinjection platform achieved rostral fixation through cortical screw fixation to a hinged occipital bone plate. Based on observations made during the initial lumbar and subsequent cervical microinjections, a modified injector stage ( Figure 2B and 2E) was designed to augment orthogonal cord entry by providing axial angle correction. The Narishige MO-97 is interchangeable between the injector stages, as shown in Figure 2A and 2B. Figure 4 demonstrates the b2 platform. This advancement incorporated improved plating for occipital fixation and a new injector stage, shown in Figure 2C and 2F. The b2 platform stage uses a Narishige MO-900, notable because it does not require hydraulic actuation and is capable of small sagittal and axial angle corrections.
Early-Generation Platform and Injection Stage Designs

Intraspinal Targeting Approaches and Injection Cannula Evolution
We adapted the techniques of deep brain electrophysiological mapping to the spinal cord in our first attempt to target the ventral horn for biological payload delivery. MER was performed in 7 adult swine with a commercially available Alpha Omega microrecording electrode (Alpha Omega Ltd.) after an L3-L5 laminectomy. 9 Unlike humans, the porcine conus medullaris and thus spinal cord terminate at the sacrum. As the electrode penetrated the spinal cord, electrical signals from single neuronal units and background activity were filtered, preamplified, and digitized for real-time monitoring. Action potential morphologies of single units, fiber activity, and background changes were quantified and recorded. Gray matter was distinguished from white matter, allowing localization of the gray/white junction. However, the multiple penetrations and prolonged cord penetration times necessary to achieve MER-based mapping resulted in an unacceptably high morbidity, even for delivery of a single graft.
Subsequent targeting for all cervical and lumbar approaches has been accomplished through the use of anatomic surface landmarks combined with an understanding of injection trajectory, including point of entry, depth of penetration, and angle of cannula entry. A series of porcine cervical injections with the b/b2 platform and a rigid cannula assembly have delivered both cellular payloads and viral vector. 8, 10, 11 Each of the above-referenced lumbar or cervical studies undertaken with either the a or b platform used a stepped, rigid, 29-gauge microinjection cannula to achieve unilateral lumbar or cervical microinjection ( Figure 5A, top) . The inner cannula was ensheathed within a larger 27-gauge outer cannula and connected proximally to 1 m of 29-gauge Silastic tubing and a Hamilton syringe (Hamilton Co, Reno, Nevada). A p99 Harvard programmable microinjection pump (Harvard, Inc) was used for precise microinjection volume delivery. With this b version and rigid cannula, no lasting neurological morbidity was observed with a maximum of 10 sequential unilateral injections, thereby providing safety validation for the feasibility of this targeting approach and therapeutic delivery technique. 10 However, consistent intraoperative observation of cardiovascular-related spinal cord pulsation in both the cervical and lumbar spinal cord, as well as respiratory-related movements, prompted the development of an injection cannula capable of accommodating inherent micromovements of the spinal cord during surgery. Detailed below, the current ''floating cannula'' design has resulted in both improved accuracy and reduced invasiveness of cord penetration.
CURRENT PLATFORM g Thoracolumbar Microinjection Platform
Each component of the current-generation thoracolumbar g platform represents a thoughtful adaptation of ''best practice'' approaches developed from our prior experiences with both the a and b/b2 platforms in concert with conceptually new innovations.
A primary shortcoming of the a and b platforms has been the need for a broad exposure to accommodate rigid spinal or spinal/ occipital fixation. Figure 5A through 5D shows the g platform to be significantly larger and more complex but also to offer several improvements over previous platforms. Broad changes reflected in this design include the incorporation of a self-retaining retractor system as part of the platform base, rostrocaudal percutaneous bony platform attachment with translaminar screws remote from the injection site seen in Figure 5A (far left), and a rail system and injection stage that are elevated above the incision. These changes have significantly reduced incision size (eg, 10 vs 16 cm), 9 improved construct rigidity, and reduced procedural complexity. Figure 5C and 5D demonstrate the platform in place, highlighting these improvements. Furthermore, performance of multiple FIGURE 4. The b2 (cervical) microinjection platform attached to the occiput and C7 on a model of human spine with a C3-4 laminectomy defect. Notably, the b2 platform has more stable occipital fixation with a multipronged bone plate and a new injector stage capable of both mediolateral and rostrocaudal angle adjustment. A and B, side and three-quarters views of the platform, stage, and MO-900 mechanical microdrive. C and D, side and three-quarters views with the rigid cannula attached.
unilateral or bilateral injections is quickened as a result of both increased device rigidity and improved platform accessibility. Figure 6A through 6C demonstrates a new full articulation micromanipulator. Features include a fully autoclavable design, fixation points for the inner and outer cannula, improved full locking articulation bearing, on-device mechanical fine-movement cannula adjustment, and low-profile locks onto the injector stage. This improved micromanipulator allows free articulation and can be locked at any position, allowing full compensation for imperfect platform placement.
Floating Cannula
The floating cannula ( Figure 7A and 7B) was designed to reduce the invasiveness of spinal cord cannulation and microinjection. This cannula contains a low-profile flanged and beveled needle of a fixed length capable of maintaining its position with beat-to-beat spinal cord pulsation and respiration-associated cord movement ( Figure 7C ). The assembly consists of a 30-gauge beveled needle connected to 1 m of 30-gauge flexible Silastic tubing. The proximal end is fitted with a Hamilton luer lock attached to a Tritech Research microInjector System programmable syringe pump (Tritech Research, Inc, Los Angeles, California). The distal Silastic tubing is ensheathed within a 24-gauge rigid outer cannula that seats on the proximal end of the injection needle flange. This flange both seats the outer cannula and serves as a depth stop for the injection needle. Figure 7B (bottom) also illustrates a newer version of the floating cannula with an enlarged flange diameter and longer proximal flange depth. These changes were designed to further improve the stability of the cord entry angle during parenchymal penetration, as seen in Figure 8 . Needle length is constant (4 mm) on each floating cannula to prevent target overshoot but can be varied between each cannula (3-5 mm) to accommodate variance in target depth according to preoperative magnetic resonance imaging (see Figure 7A and 7B).
Current-Generation Platform/Cannula Outcomes Safety Outcomes.
Except for an initial published study using MER-based targeting, 9 . 100 tested swine have returned to neurological baseline by 7 to 10 postoperative days with the Tarlov motor grading scale. This has included variance of site (eg, cervical vs lumbar), immunosuppressant regimen (eg, none, single agent, or multiagent regimen), study end point ranging from 1 week to 1 month, biological payload (eg, cellular or viral delivery), and single vs multiple unilateral injections. We extend these findings to include return to neurological baseline using both the g platform and floating cannula with both multiple unilateral or bilateral lumbar microinjections.
Accuracy Outcomes. Figure 8 provides an illustration of microinjection epicenters from separate experimental series. Figure 8A is a composite (n = 17) of observed injection sites using a rigid cannula to achieve unilateral cervical microinjections. It is compiled from 3 subgroups (6 farm pigs per group) with varying injection volumes. Figure 8B is a composite of unilateral cervical microinjections (n = 11 Gottingen minipigs) using a rigid cannula. Figure 8C demonstrates the use of the floating cannula with a multilevel lumbar injection series (n = 4 or 5 injections per animal (2-mm interval; n = 5 minipigs). Comparing Figure 8A and 8B with Figure 8C indicates that the use of the floating cannula has not detrimentally affected accuracy and is characterized by an overall tighter clustering of injection epicenters within the central or ventral gray matter. This FIGURE 5. The microinjection platform. A, far left, the laminar bone screws with the associated nuts. Far right, sheaths and spacers for the bone screws. Right and left, self-retaining retractors with 4 holes for alignment with the translaminar screws/sheaths and platform rail system. Top, 2 of 4 required retractor arms and blades. Far bottom, tunnelers to dock the laminar screw sheaths on the lamina before screw introduction. Bottom, the gondola platform to mount the microinjector platform on the platform rail system. Center, the platform rail system and microinjector. B, in situ demonstration of the g platform without the attached retractor arms/blades. C, in vivo demonstration of the g platform before the laminectomy and before attachment of the gondola or microinjector platform. D, in vivo demonstration of the fully assembled microinjection platform.
is attributable to the combined use of the floating cannula and g platform, allowing nearly identical injection trajectories in rapid succession and with minimal device modification.
INTO THE FUTURE
Design, construction, testing, and refinement of the above devices have contributed to the preclinical safety validation of a stabilized microinjection approach for targeted delivery of biological payloads to the human spinal cord. This need is apparent given both the rapid advances in development of potential biological therapeutics and the spectrum of oncologic, traumatic, and neurodegenerative lesions that are currently uncontrolled with available medical and surgical treatments. Over the preceding 4 years, we have developed a safe and accurate targeted strategy for delivery of biological therapeutics to the spinal cord in either 1 or multiple sequential injections. The newest refinements, the g platform and floating cannula, have reduced the ''operative footprint'' both anatomically and temporally by decreasing the required exposure and the complexity of performing multiple injections. On the basis of our prior work, [8] [9] [10] [11] unpublished Good Laboratory Practice studies, and data from other Injection cannulas of different lengths are fabricated, depending on the expected target depth. C, retraction of the outer cannula demonstrates a longer proximal flange and a more heavily tapered bevel at the cannula tip. The longer flange helps to maintain orthogonal cord entry during retraction of the outer cannula, and the tapered bevel improves pial penetration and prevents the need for separate pial separation.
experimental series characterizing the g platform and floating cannula, this technology and approach are currently being tested in a Food and Drug Administration-approved phase I clinical trial to deliver fetal neural stem cells to the thoracolumbar ventral horn for amyotrophic lateral sclerosis.
12 Clinical translation will provide both useful feedback for evaluation of swine as a faithful preclinical large-animal model and a foundation for further innovation to improve targeted intraspinal microinjection techniques. Near-term goals will focus on adapting the g platform and floating cannula for cervical application. Longer-term efforts will continue the pursuit of less invasive approaches using magnetic resonance imaging or computed tomography guidance and examination of strategies for nearly real-time confirmation of targeting accuracy through better electrophysiological monitoring and radiographic verification.
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